Cognitiplus
Introduce
Cognitiplus is a special supplements for brain health. As active ingredient, SynapsaTM is a patented, standardized extract of Bacopa monieri with more than 30 years of clinical studies that has been shown to help support an improvement in visual processing, learning rate, working memory, information retention and mental performance in cognitively demanding environments such as test-taking. Synapsa supplements can help decrease the rate of forgetfulness and improve multitasking accuracy.*
Studies show support for two distinct types of benefit from Synapsa Natural Memory Support: daily, long-term use (chronic) to enhance learning and memory, and short-term use (acute) to improve mental performance in cognitively demanding environments such as test-taking.*
Bacopa monnieri is a common herb used in traditional Ayurveda medicine.The main mechanism of Bacopa monnieri involves the promotion of neuron communication. Bacopa monnieri increases the growth of nerve endings, known as dendrites, thereby increasing the rate at which the brain can communicate with your body.
Bacopa monnieri is also categorized as an adaptogen. Adaptogens are natural substances that are designed to block stress chemicals that trigger negative effects to your physiology. It does this by specifically reducing the amount of the biomarker HSP70. This ultimately decreases how much stress you and your brain perceive, allowing you to better adapt to potential stressors in your environment.
The herb also interacts with the neurotransmitters dopamine and serotonin. Dopamine is responsible for a wide range of functions, commonly involved in processes like motivation and muscle control. Serotonin is responsible for maintaining mental balance
This product is only for distributors and wholesalers
- *This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions.
Research
Here, you can read some of important published clinical research papers about SynapsaTM , which support brain health. Published peer reviewed studies can be accessed through PubMed at www.ncbi.nlm.nih.gov/pubmed. For more information, please contact Renylin Bio-Health Inc.
Significantly improves speed of visual information processing, learning rate, memory consolidation
The chronic effects of an extract of Bacopa monniera on cognitive function in healthy human subjects
Abstract.
Rationale: Extracts of Bacopa monniera have been reported to exert cognitive enhancing effects in animals. However, the effects on human cognition are inconclusive. Objective: The current study examined the chronic effects of an extract of B. monniera (Keenmind) on cognitive function in healthy human subjects. Methods: The study was a double-blind placebo-controlled independent-group design in which subjects were randomly allocated to one of two treatment conditions, B. monniera (300 mg) or placebo. Neuropsychological testing was conducted pre-(baseline) and at 5 and 12 weeks postdrug administration. Results: B. monniera significantly improved speed of visual information processing measured by the IT task, learning rate and memory consolidation measured by the AVLT (P<0.05), and state anxiety (P<0.001) compared to placebo, with maximal effects evident after 12 weeks. Conclusions: These finding suggests that B. monniera may improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory.
Stough et al. The chronic effects of an extract of Bacopa monniera on cognitive function in healthy human subjects, Psychopharmacology, 2001; 156:481-484.
A significant decrease in the rate of forgetting newly acquired information in individuals taking Synapsa.
Chronic effects of Brahmi on human memory
A study is reported on the effects of Brahmi (Bacopa monniera) on human memory. Seventy-six adults aged between 40 and 65 years took part in a double-blind randomized, placebo control study in which various memory functions were tested and levels of anxiety measured. There were three testing sessions: one prior to the trial, one after three months on the trial, and one six weeks after the completion of the trial. The results show a significant effect of the Brahmi on a test for the retention of new information. Follow-up tests showed that the rate of learning was unaffected, suggesting that Brahmi decreases the rate of forgetting of newly acquired information. Tasks assessing attention, verbal and visual short-term memory and the retrieval of pre-experimental knowledge were unaffected. Questionnaire measures of everyday memory function and anxiety levels were also unaffected.
Source：Roodenrys et al. Neuropsychopharmacology, 2002; 27:279-281.
Significant improvement of mental control, logical memory and paired associated learning
Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment
Abstract
Background: Brahmi (Bacopa monniera) is a traditional Indian medicinal plant which causes multiple effects on the central nervous system. The standardized extract of this plant has shown enhanced behavioural learning in preclinical studies and enhanced information processing in healthy volunteers.
Aim: To study the efficacy of standardized Bacopa monniera extract (SBME) in subjects with age-associated memory impairment (AAMI) without any evidence of dementia or psychiatric disorder.
Methods: A double-blind, placebo-controlled randomized study design was employed. The subjects received either 125 mg of SBME or placebo twice a day for a period of 12 weeks followed by a placebo period of another 4 weeks (total duration of the trial 16 weeks). Each subject was evaluated for cognition on a battery of tests comprising mental control, logical memory, digit forward, digit backward, visual reproduction and paired associate learning.
Results: SBME produced significant improvement on mental control, logical memory and paired associated learning during the 12-week drug therapy.
Conclusion: SBME is efficacious in subjects with age-associated memory impairment.
Source: Raghav et al. Indian Journal of Psychiatry, 2006; 48:238-242.
Significant improvement of performance on tests of working memory and visual information processing
Examining the Nootropic Effects of a special extract of Bacopa monniera on Human Cognitive Functioning
While Ayurvedic medicine has touted the cognitive enhancing effects of Bacopa monniera for centuries, there is a need for double-blind placebo-controlled investigations. One hundred and seven healthy participants were recruited for this double-blind placebo-controlled independent group design investigation. Sixty-two participants completed the study with 80% treatment compliance. Neuropsychological testing using the Cognitive Drug Research cognitive assessment system was conducted at baseline and after 90 days of treatment with a special extract of Bacopa monniera (2 × 150 mg KeenMind) or placebo. The Bacopa monniera product significantly improved performance on the ‘Working Memory’ factor, more specifically spatial working memory accuracy. The number of false-positives recorded in the Rapid visual information processing task was also reduced for the Bacopa monniera group following the treatment period. The current study provides support for the two other published studies reporting cognitive enhancing effects in healthy humans after a 90 day administration of the Bacopa monniera extract. Further studies are required to ascertain the effective dosage range, the time required to attain therapeutic levels and the effects over a longer term of administration.
Source:Stough et al.Phytotherapy Research, 2008; 22:1629-1634.
Improved performance for the CDB in participants consuming the 320 mg dose of Synapsa
An Acute, Double-Blind, Placebo-Controlled Crossover Study of 320 mg and 640 mg Doses of a Special Extract of Bacopa monnieri (CDRI 08) on Sustained Cognitive Performance
Abstract
Standardized extracts of the traditional Ayurvedic medicine Bacopa monnieri (BM) (Brahmi) have been recently shown to have cognitive enhancing effects in chronic administration studies. Pre-clinical work has also identified a number of acute anxiolytic, nootropic, and cardiovascular effects of BM. There has, however, been little research on the acute effects of BM on cognitive function. The current study aimed to assess the acute effects of a specific extract of BM (KeenMindW - CDRI 08) in a double-blind, placebo-controlled study in normal healthy participants who completed a cognitively demanding series of tests. Twenty-four healthy volunteers completed six repetitions of the Cognitive Demand Battery (CDB) after consuming a placebo, 320mg BM or 640mg of BM in a cross-over design and provided cardiovascular and mood assessments before and after treatment. Change frombaseline scores indicated that the 320mg dose ofBMimproved performance at the first, second, and fourth repetition post-dosing on the CDB, and the treatments had no effect upon cardiovascular activity or in attenuating task-induced ratings of stress and fatigue. It was concluded that assessment of an earlier pharmacological window and use of less memory-specific cognitive tests together with more temporally sensitivemeasures of brain activity may improve our understanding of the acute neurocognitive properties of BM.
Source：Downey et al. Phytotherapy Research 2012; 27:1407-1413.
Positive cognitive effects in measures of cognitive function, mood and cortisol levels
An Acute, Double-Blind, Placebo-Controlled Cross-over Study of 320 mg and 640 mg Doses of Bacopa monnieri (CDRI 08) on Multitasking Stress Reactivity and Mood.
Abstract
Little research exists in humans concerning the anxiolytic, antidepressant, sedative, and adaptogenic actions the traditional Ayurvedic medicine Bacopa monnieri (BM) possesses in addition to its documented cognitive-enhancing effects. Preclinical work has identified a number of acute anxiolytic, nootropic, and adaptogenic effects of BM that may also co-occur in humans. The current double-blind, placebo-controlled cross-over study assessed the acute effects of a specific extract of BM (KeenMind® - CDRI 08) in normal healthy participants during completion of a multitasking framework (MTF). Seventeen healthy volunteers completed the MTF, at baseline, then 1 h and 2 h after consuming a placebo, 320 mg BM and 640 mg of BM. Treatments were separated by a 7-day washout with order determined by Latin Square. Outcome measures included cognitive outcomes from the MTF, with mood and salivary cortisol measured before and after each completion of the MTF. Change from baseline scores indicated positive cognitive effects, notably at both 1 h post and 2 h post BM consumption on the Letter Search and Stroop tasks, suggesting an earlier nootropic effect of BM than previously investigated. There were also some positive mood effects and reduction in cortisol levels, pointing to a physiological mechanism for stress reduction associated with BM consumption. It was concluded that acute BM supplementation produced some adaptogenic and nootropic effects that need to be replicated in a larger sample and in isolation from stressful cognitive tests in order to quantify the magnitude of these effects.
Source：Benson S, Downey LA, Stough C et al. Phytotherapy Research 2013.
Improve attention, cognitive processing, and working memory via suppression of AChE activity
Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers
Abstract
At present, the scientific evidence concerning the effect of Bacopa monnieri on brain activity together with working memory is less available. Therefore, we aimed to determine the effect of B. monnieri on attention, cognitive processing, working memory, and cholinergic and monoaminergic functions in healthy elderly. A randomized double-blind placebo-controlled design was utilized. Sixty healthy elderly subjects (mean age 62.62 years; SD 6.46), consisting of 23 males and 37 females, received either a standardized extract of B. monnieri (300 and 600 mg) or placebo once daily for 12 weeks. The cholinergic and monoaminergic systems functions were determined using AChE and MAO activities. Working memory was assessed using percent accuracy and reaction time of various memory tests as indices, whereas attention and cognitive processing were assessed using latencies and amplitude of N100 and P300 components of event-related potential. All assessments were performed before treatment, every four weeks throughout study period, and at four weeks after the cessation of intervention. B. monnieri-treated group showed improved working memory together with a decrease in both N100 and P300 latencies. The suppression of plasma AChE activity was also observed. These results suggest that B. monnieri can improve attention, cognitive processing, and working memory partly via the suppression of AChE activity.
Source：Evid Based Complement Alternat Med. 2012;2012:606424. doi: 10.1155/2012/606424. Epub 2012 Dec 18.
Safely enhancing cognitive performance in the aging
Effects of a Standardized Bacopa monnieri Extract on Cognitive Performance, Anxiety,and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
Objectives: Study aims were to evaluate effects of Bacopa monnieri whole plant standardized dry extract on cognitive function and affect and its safety and tolerability in healthy elderly study participants.
Design: The study was a randomized, double-blind, placebo-controlled clinical trial with a placebo run-in of 6 weeks and a treatment period of 12 weeks.
Setting/location: Volunteers were recruited from the community to a clinic in Portland, Oregon by public notification.
Subjects: Fifty-four (54) participants, 65 or older (mean 73.5 years), without clinical signs of dementia, were recruited and randomized to Bacopa or placebo. Forty-eight (48) completed the study with 24 in each group.
Interventions: Standardized B. monnieri extract 300 mg/day or a similar placebo tablet orally for 12 weeks.
Outcome measures: The primary outcome variable was the delayed recall score from the Rey Auditory Verbal Learning Test (AVLT). Other cognitive measures were the Stroop Task assessing the ability to ignore irrelevant information, the Divided Attention Task (DAT), and the Wechsler Adult Intelligence Scale (WAIS) letter-digit test of immediate working memory. Affective measures were the State-Trait Anxiety Inventory, Center for Epidemiologic Studies Depression scale (CESD)-10 depression scale, and the Profile of Mood States. Vital signs were also monitored.
Results: Controlling for baseline cognitive deficit using the Blessed Orientation–Memory–Concentration test, Bacopa participants had enhanced AVLT delayed word recall memory scores relative to placebo. Stroop results were similarly significant, with the Bacopa group improving and the placebo group unchanged. CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreased over time for the Bacopa group but increased for the placebo group. No effects were found on the DAT, WAIS digit task, mood, or blood pressure. The dose was well tolerated with few adverse events (Bacopa n=9, placebo n=10), primarily stomach upset.
Conclusions: This study provides further evidence that B. monnieri has potential for safely enhancing cognitive performance in the aging.
Source:The Journal of Alternative and Complementary Medicine Volume 14, Number 6, 2008, pp. 707–713
FAQs
Synapsa is an active ingredient in CognitiPlus. Synapsa Natural Memory Support is a unique, standardized extract of Bacopa monnieri, with a wide range of active constituents that contribute to its properties of supporting memory, learning and intellectual performance. Bacopa monnieri (also known as brahmi) is an herb that has been used in traditional Ayurvedic medicine for centuries.
Synapsa is a patented, standardized extract of Bacopa monieri with more than 30 years of clinical studies that has been shown to help support an improvement in visual processing, learning rate, working memory, information retention and mental performance in cognitively demanding environments such as test-taking. Synapsa supplements can help decrease the rate of forgetfulness and improve multitasking accuracy.*
The studies on Synapsa have been conducted on a very wide range of ages – from 18 to 65 and even older. That means that anyone who wants to improve their ability to learn and remember information should consider it – as well as those who want to improve their mental performance, particularly in ‘multi-tasking’ environments.
Today’s proprietary Synapsa ingredient is based on a patented extraction process that follows an exacting farming and manufacturing process to ensure a standardized level of quality – since each step of this process can influence the final product’s complex phytochemical profile and therapeutic action. Putting farming & manufacturing controls in place across each step achieves product consistency & results in a product that can be and has been clinically studied.
Long-term (90 day) studies have consistently used 320 mg Synapsa/day while higher doses (640 mg) have been used to evaluate acute or short-term benefits of Synapsa. The amount of Synapsa may vary in formulated products.
For some, cognitive enhancement may be noticed relatively quickly. Studies have shown improved mental performance in as little 2 hours after taking Synapsa. Longer term studies focusing on memory improvement and better learning have shown results after 90 days of daily use of Synapsa. Continued daily use of Synapsa offers on-going support for improved cognitive performance.
Synapsa has been studied in laboratory and clinical trials for over 30 years. It has been shown to be well tolerated in studies at the commonly recommended dosages– with no serious side effects reported. In rare cases, mild gastric upset could occur if Synapsa is not taken with food.
Definitely not. Synapsa is made by a proprietary, patented process that controls everything from seeds to extraction technique. Unlike synthetic medicines, natural compounds will vary widely due to the habitat of the plant, the parts of the plant that are used, growing, harvesting and production conditions.
The studies that are discussed on this website were specifically conducted on Synapsa. You cannot be sure that other ingredients that call themselves Bacopa monnieri will behave the same way in use. You should be careful to check the scientific studies that are associated with any supplement ingredient you are considering. Sometimes, companies will ‘borrow’ science by claiming that their product works the same way as another product with a similar name. When companies do this, they are actually misleading you!
- *This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions.